EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Cutting edge developments and novel targets in IBD: Microbiome in IBD

Sara Deleu, João Sabino

Best Practice & Research Clinical Gastroenterology · 2025

DOI: 10.1016/j.bpg.2025.102060 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Best Practice & Research Clinical Gastroenterology, 2025. Verfasst von Sara Deleu und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chronic Diseases, and Metabolism (CHROMETA), KU Leuven, Leuven, Belgium. Electronic address: sara.deleu@kuleuven.be. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Inflammatory Bowel Diseases, Crohn Disease, Colitis, Ulcerative. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 115 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fonds Wetenschappelijk Onderzoek.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Inflammatory bowel disease (IBD), a non-communicable disease encompassing Crohn's disease and ulcerative colitis, is a chronic disorder with increasing prevalence and complex etiology. Emerging evidence highlights the gut microbiome's pivotal role in IBD pathogenesis, driving interest in microbiome-targeted therapeutic strategies. This narrative review explores the latest advancements in microbiome modulation for IBD management, encompassing antibiotics, prebiotics, probiotics, synbiotics, postbiotics, and fecal microbiota transplantation. Additionally, dietary interventions, physical activity, as well as non-bacterial microbiota components such as fungi, archaea, and bacteriophages are examined for their potential roles in restoring microbial equilibrium and mitigating intestinal inflammation. As research progresses, a multimodal approach integrating microbiota-targeted therapies with lifestyle modifications and conventional pharmacologic treatments may offer a personalized and effective strategy for IBD management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gastrointestinal MicrobiomeInflammatory Bowel DiseasesCrohn DiseaseColitis, UlcerativeHumansProbioticsFecal Microbiota TransplantationPrebioticsAnti-Bacterial AgentsSynbiotics

Substanzen

PrebioticsAnti-Bacterial Agents

Autor:innen und Institutionen

  • Department of Chronic Diseases, and Metabolism (CHROMETA), KU Leuven, Leuven, Belgium. Electronic address: sara.deleu@kuleuven.be.
  • Department of Chronic Diseases, and Metabolism (CHROMETA), KU Leuven, Leuven, Belgium; Department of Gastroenterology and Hepatology, University Hospitals Leuven, KU Leuven, Leuven, Belgium. Electronic address: joao.sab…

Förderung

  • Fonds Wetenschappelijk Onderzoek

Zitieren

APA

Deleu, S., & Sabino, J. (2025). Cutting edge developments and novel targets in IBD: Microbiome in IBD. Best Practice & Research Clinical Gastroenterology. https://doi.org/10.1016/j.bpg.2025.102060

Vancouver

Deleu S, Sabino J. Cutting edge developments and novel targets in IBD: Microbiome in IBD. Best Practice & Research Clinical Gastroenterology. 2025. doi:10.1016/j.bpg.2025.102060

BibTeX
@article{Deleu2025,
  author = {Deleu, Sara and Sabino, João},
  title = {Cutting edge developments and novel targets in IBD: Microbiome in IBD},
  journal = {Best Practice & Research Clinical Gastroenterology},
  year = {2025},
  doi = {10.1016/j.bpg.2025.102060}
}
Kostenlos starten →